AMP German Cannabis Group announces AGM Results and Appointment of New CFO

Published: June 30, 2020

AMP German Cannabis Group announces AGM Results and Appointment of New CFO

AMP German Cannabis Group Inc. held its annual general meeting of shareholders (AGM) earlier today.  The shareholders approved all resolutions put before them, namely:

  • Re-electing Dr. Stefan Feuerstein and Messrs. Alex BlodgettClaudio Morandi and Kenneth MacLeod as directors of the Company;
  • Re-appointed Dale Matheson Carr-Hilton Labonte LLP, Chartered Accountants, as the Company’s auditor for the ensuing year and authorizing the directors to set the auditor’s remuneration.

After the AGM, AMP published a pre-recorded online question and answer session with Dr. Stefan Feuerstein, President and Director of AMP. Watch video on the following link: https://youtu.be/akQ5tJqBvVU

AMP also announces the appointment of Mr. Nick Furber as Chief Financial Officer (CFO) and as a new member to its board of directors. Mr. Furber will oversee financial aspects of the company, including financial planning and analysis, accounting, and financial reporting, managing tax, treasury, internal audit, and investor relations.

Mr. Furber has over two decades of experience in financial reporting, management, corporate finance, and business development in multiple industries including medical, mining, and financial services and has been the CFO for companies listed in CanadaGermany and the United States.  Previously, Mr. Furber worked for PricewaterhouseCoopers in the United Kingdom and Canada, primarily in their Corporate Finance and Transaction Services groups.  Mr. Furber is a Chartered Accountant (ICAEW) and Chartered Financial Analyst (CFA) charter holder.

Mr. Alex Blodgett, CEO & Director, commented, “We would like to thank Ms. Christine McPhie for her contribution as the Company’s CFO and her help in ensuring an orderly transition. We wish Ms. McPhie all the best in her retirement.”

AMP German Cannabis Group is licensed to import European Union – Good Manufacturing Practice (EU-GMP) medical cannabis and sell to pharmaceutical distributers or pharmacists directly, the only point-of-sale for medical cannabis to German patients.